Abstract
Peripheral neuropathy remains a major cause of morbidity and is a cardinal factor in the pathogenesis of diabetic foot ulceration. The aim of the present study was to compare the new indicator test for sudomotor function (Neuropad® ) with the vibration perception threshold (VPT) and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. This study included 154 type 2 diabetic patients (76 men) with a mean age of 64.3±7.3 years and a mean diabetes duration of 12.8±4.3 years. Neuropathy was diagnosed clinically using the Neuropathy Disability Score (NDS). The VPT was measured with a neurothesiometer, values25Volts being classified as abnormal. Sudomotor function was evaluated by the indicator test. Sensitivity of the indicator test for neuropathy was 97.8% and specificity was 67.2%. Sensitivity and specificity of VPT for neuropathy were 78.9% and 85.9% respectively. A significant correlation was shown between time to colour change of the indicator test and VPT (rs =0.889, p<0.001).
Conclusions: Both the indicator test and the VPT have a high sensitivity for neuropathy. Sensitivity is higher with the indicator test, but specificity is higher with VPT. Time until complete colour change of the indicator test shows a positive correlation with VPT. Thus, the indicator test appears to be a useful additional diagnostic tool of neuropathy, particularly suitable for screening and self-examination, in type 2 diabetes. The correlation between time to colour change of the indicator test and VPT is interesting and merits investigation in a prospective study.
Key words
Diabetes mellitus - diabetic foot - diabetic neuropathy - sudomotor function
References
1
Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ.
Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration.
Diabetes Care.
1998;
21
1071-1075
2
Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J. et al .
The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort.
Diabet Med.
2002;
19
377-384
3
Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG.
Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.
Arch Intern Med.
1998;
158
289-292
4
Boulton AJM, Kirsner RS, Vileikyte L.
Neuropathic diabetic foot ulcers.
N Engl J Med.
2004;
351
48-55
5
Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. American Diabetes Association .
Diabetic neuropathies: a statement by the American Diabetes Association.
Diabetes Care.
2005;
28
956-962
6
Braune HJ, Horter C.
Sympathetic skin response in diabetic neuropathy: a prospective clinical and neurophysiological trial on 100 patients.
J Neurol Sci.
1996;
138
120-124
7
Bril V, Perkins BA.
Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies.
Diabet Med.
2002;
19
661-666
8
Davis EA, Jones TW, Walsh P, Byrne GC.
The use of biothesiometry to detect neuropathy in children and adolescents with IDDM.
Diabetes Care.
1997;
20
1448-1453
9
Edmonds ME.
The diabetic foot, 2003.
Diabetes Metab Res Rev.
2004;
20
(Suppl 1)
S9-S12
10
Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B. et al .
The AGE/RAGE/NF-(kappa) B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT).
Exp Clin Endocrinol Diabetes.
2005;
113
288-291
11
Jurado J, Ybarra J, Pou JM.
Isolated use of vibration perception thresholds and Semmes Weinstein monofilament in diagnosing diabetic polyneuropathy: “the North Catalonia diabetes study”.
Nurs Clin North Am.
2007;
42
59-66
12
Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ.
Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration.
Diabetes Res Clin Pract.
1991;
13
63-67
13
Manes C, Mikoudi K, Sossidou E, Pigas G, Karagianni D, Skoutas D, Fotiadis S.
Evaluation of a new indicator plaster in identifying diabetic patients at risk of foot ulceration.
Diabetologia.
2004;
47
((Suppl 1))
A376
14
Marinou K, Maggana S, Liatis S, Nikolopoulos A, Diakoumopoulou E, Tentolouris N. et al .
Usefulness of the indicator plaster Neuropad for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus.
Diabetologia.
2005;
48
((Suppl 1))
A995
15
Paisley AN, Abbott CA, van Schie CH, Boulton AJ.
A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function.
Diabet Med.
2002;
19
400-405
16
Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H. et al .
Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients.
Exp Clin Endocrinol Diabetes.
2005;
113
195-198
17
Papanas N, Papatheodorou K, Papazoglou D, Christakidis D, Monastiriotis C, Maltezos E.
Reproducibility of the new indicator test for sudomotor function (Neuropad) in patients with type 2 diabetes mellitus: short communication.
Exp Clin Endocrinol Diabetes.
2005b;
113
577-581
18
Papanas N, Gries A, Maltezos E, Zick R.
The steel ball-bearing test: a new test for evaluating protective sensation in the diabetic foot.
Diabetologia.
2006;
49
739-743
19
Papanas N, Giassakis G, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D. et al .
Use of the new indicator test (Neuropad) for the assessment of the staged severity of neuropathy in type 2 diabetic patients.
Exp Clin Endocrinol Diabetes.
2007;
115
58-61
20
Papanas N, Papatheodorou K, Papazoglou D, Christakidis D, Monastiriotis C, Maltezos E.
The new indicator test (Neuropad): a valuable diagnostic tool for small-fiber impairment in patients with type 2 diabetes.
Diabetes Educ.
2007b;
33
257-258
, 260, 262 passim.
21
Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Christakidis D, Maltezos E.
An insertion/deletion polymorphism in the alpha2b adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus.
Exp Clin Endocrinol Diabetes.
2007c;
115
327-330
22
Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A.
Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial.
Diabetes Care.
2000;
23
606-611
23
Rith-Najarian SJ, Stolusky T, Gohdes DM.
Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria.
Diabetes Care.
1992;
15
1386-1389
24
Shimada H, Kihara M, Kosaka S, Ikeda H, Kawabata K, Tsutada T. et al .
Comparison of SSR and QSART in early diabetic neuropathy: value of length-dependent pattern in QSART.
Auton Neurosci.
2001;
92
72-75
25
Veves A, Manes C, Murray HJ, Young MJ, Boulton AJ.
Painful neuropathy and foot ulceration in diabetic patients.
Diabetes Care.
1993;
16
1187-1189
26
Vileikyte L, Hutchings G, Hollis S, Boulton AJ.
The tactile circumferential discriminator. A new, simple screening device to identify diabetic patients at risk of foot ulceration.
Diabetes Care.
1997;
20
623-626
27
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH.
A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.
Diabetologia.
1993;
36
150-154
28
Young MJ, Breddy JL, Veves A, Boulton AJ.
The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study.
Diabetes Care.
1994;
17
557-560
29
Zick R, Schäper T, Deeters U.
Periphere diabetische Neuropathie. Die Schweißsekretion am Fuß messen.
Klinikarzt.
2003;
32
192-194
30
Zimny S, Pfohl M.
Healing times and prediction of wound healing in neuropathic diabetic foot ulcers: a prospective study.
Exp Clin Endocrinol Diabetes.
2005;
113
90-93
Correspondence
Dr. N. Papanas
Ethnikis Antistasis 44
68100 Alexandroupolis
Greece
Phone: +30/255/108 49 72
Fax: +30/255/107 47 23
Email: papanasnikos@yahoo.gr